Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study.
Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Society's Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
JERUSALEM, October 20/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc.(OTCBB: ORMP.OB; http://www.oramed.com), a developer of oral drug delivery systems, announced today that its poster entitled "A novel GLP-1 analog delivered orally reduces postprandial glucose excursions in a porcine model," has been accepted for presentation at the Diabetes Technology Society's Ninth Annual Meeting in San Francisco, California between November 5-7, 2009.
"The selection of Oramed as one of the companies to present at theDiabetes Technology Conference is a wonderful opportunity for us todemonstrate our technology to the world's leading diabetes scientists," saidNadav Kidron, Oramed CEO.
Oramed's abstract will be presented on Thursday November 5, 2009, at 5:30PM. The poster will be available for viewing throughout the conference.
For more information about the Diabetes Technology Society's Ninth AnnualMeeting, please visit http://www.diabetestechnology.org/
For more information about Oramed Pharmaceuticals, please visithttp://www.oramed.com
2009 Al Bawaba (www.albawaba.com)
2009 Al Bawaba (Albawaba.com)
Provided by Syndigate.info an Albawaba.com company
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 20, 2009|
|Previous Article:||Abbas in Cairo as Hamas rejects disarming military wing.|
|Next Article:||BluePhoenix Rehosting Solution Enables Volvofinans to Reduce TCO of Credit Card System by 40%,.|